Reviewing DarioHealth (NASDAQ:DRIO) & AngioDynamics (NASDAQ:ANGO)

DarioHealth (NASDAQ:DRIO) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for DarioHealth and AngioDynamics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	2	2	0	2.20
AngioDynamics	1	0	3	1	2.80

DarioHealth presently has a consensus target price of $32.00, suggesting a potential upside of 172.11%. AngioDynamics has a consensus target price of $19.33, suggesting a potential upside of 91.99%. Given DarioHealth’s higher probable upside, equities research analysts clearly believe DarioHealth is more favorable than AngioDynamics.

Insider & Institutional Ownership

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares DarioHealth and AngioDynamics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$24.73 million	3.21	-$42.75 million	($11.16)	-1.05
AngioDynamics	$307.31 million	1.35	-$33.99 million	($0.67)	-15.03

AngioDynamics has higher revenue and earnings than DarioHealth. AngioDynamics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

DarioHealth has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Profitability

This table compares DarioHealth and AngioDynamics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-171.09%	-59.47%	-36.75%
AngioDynamics	-9.02%	-2.28%	-1.50%

Summary

AngioDynamics beats DarioHealth on 11 of the 15 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About AngioDynamics

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.